RISPERDAL related Press Releases

Alkermes Announces Shareholder Vote in Favor of Merger with Elan Drug Technologies

Thu, 08 Sep 2011 11:20:37 -0400

– 99.9% of Votes Cast Were in Favor of Merger –

– Transaction Expected to Close on Sept. 16, 2011 –

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) today announced that Alkermes shareholders have approved the merger of Alkermes and Elan Drug Technologies (“EDT”), the profitable drug formulation and manufacturing business unit of Elan Corporation, plc (NYSE: ELN) (“Elan”). Both businesses will be combined under Alkermes plc, a newly formed company domiciled in Ireland. Approximately 99.9% of the votes cast by Alkermes’ shareholders were in favor of adopting the business combination agreement and plan of merger. Alkermes currently anticipates that the business combination will close on Sept. 16, 2011. Following the merger, Alkermes plc will be listed on the NASDAQ stock exchange under Alkermes’ current ticker symbol “ALKS.”

The transaction will result in the establishment of a global biopharmaceutical company that will have diverse, growing revenues from more than 20 commercial products, with near-term growth expected from RISPERDAL^® CONSTA^®, INVEGA^® SUSTENNA^®, AMPYRA^®, VIVITROL^® and BYDUREON^™. Alkermes plc is expected to be immediately profitable on a cash earnings basis and generate product, royalty and manufacturing revenues in excess of $450 million annually, leaving the company well-positioned to invest in its CNS-focused pipeline of proprietary and partnered product candidates currently in clinical development.

“The overwhelming shareholder support for this transaction underscores the value that we are creating with this transformative merger,” stated Richard Pops, Chief Executive Officer of Alkermes. “We are excited about the formation of this unique biopharmaceutical company and believe Alkermes plc is well-positioned to deliver significant growth and to develop important new medicines designed to improve patient outcomes.”

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients’ lives. Alkermes developed, manufactures and commercializes VIVITROL^® for alcohol and opioid dependence and manufactures RISPERDAL^® CONSTA^® for schizophrenia and bipolar I disorder. Alkermes’ robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Note Regarding Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements concerning future financial and operating performance, business plans or prospects of Alkermes plc; and the likelihood that the merger with EDT will close and the timing of such closing. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and the company’s business is subject to significant risk and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations.

These risks and uncertainties include among others: the possibility that the merger with EDT will not be completed because of the failure of one or more conditions; the possibility that the anticipated financial, clinical and operational benefits of the proposed merger cannot be fully realized, realized at all, or that such benefits may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Alkermes, Inc. and EDT operations will be greater than expected; the ability of the combined company to retain and hire key personnel and maintain relationships with customers, suppliers or other business partners; and the impact of legislative, regulatory, competitive and technological changes. Additional information and other factors are contained in Alkermes’ filings with the Securities and Exchange Commission (the “SEC”), including Alkermes’ Annual Reports on Form 10-K, subsequent Quarterly Reports on Form 10-Q, recent Current Reports on Form 8-K and other SEC filings, which are available at the SEC’s website at http://www.sec.gov. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating any forward-looking information contained in this press release.

VIVITROL^® is a trademark of Alkermes, Inc. RISPERDAL^® CONSTA^® and INVEGA^® SUSTENNA^® are trademarks of Janssen Pharmaceuticals, Inc. AMPYRA^® is a trademark of Acorda Therapeutics, Inc. BYDUREON^™ is a trademark of Amylin Pharmaceuticals, Inc.

CONTACT:

Alkermes
For Investors:
Rebecca Peterson, 781-609-6378
or
For U.S. Media:
Jennifer Snyder, 781-609-6166
or
For EU Media:
Mike Sinclair, +44 20 7318 2955

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Health General Health

MEDIA:

Logo

Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2012

Mon, 25 Jul 2011 16:20:29 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Monday, August 1, 2011, to discuss the company’s financial results for the first quarter of fiscal 2012. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermes’ website at www.alkermes.com or may be accessed by dialing 1-888-424-8151 for domestic callers and 1-847-585-4422 for international callers. The conference call ID number is 6037988.

A replay of the conference call will be available from 7:30 p.m. ET on Monday, August 1, 2011, through 5:00 p.m. ET on Monday, August 8, 2011, and may be accessed by visiting Alkermes’ website or by dialing 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The replay access code is 6037988.

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL^® for alcohol and opioid dependence and manufactures RISPERDAL^® CONSTA^® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

VIVITROL^® is a trademark of Alkermes, Inc. RISPERDAL^® CONSTA^® is a trademark of Janssen-Cilag group of companies.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical General Health

MEDIA:

Logo

Alkermes to Webcast Analyst and Investor Day

Mon, 11 Jul 2011 16:28:53 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) today announced that it will webcast its Analyst and Investor Day being held on Monday, July 18, 2011, at the Boston Harbor Hotel. The webcast will begin at 3:00 p.m. ET and conclude at approximately 5:00 p.m. ET. At the meeting, members of Alkermes’ senior management and a guest speaker from Elan Drug Technologies (EDT) will provide an update on the merger of Alkermes and EDT, including the combined company’s outlook, commercial products, pipeline candidates and financial expectations.

A live webcast of the event will be available on the investor relations section of the company's website at www.alkermes.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start. This webcast will be archived on the Alkermes website.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Research Science General Health

MEDIA:

Logo

Alkermes' Corporate Presentation to be Webcast at the NASDAQ OMX 26th Investor Program

Tue, 14 Jun 2011 16:28:36 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the NASDAQ OMX 26th Investor Program on Tuesday, June 21, 2011, at 8:30 a.m. BST (3:30 a.m. ET) from the May Fair Hotel in London. The presentation may be accessed under the investor relations tab at www.alkermes.com and will be archived for 14 days.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Biotechnology Professional Services Finance

MEDIA:

Logo

Alkermes’ Corporate Presentation to Be Webcast at Two Upcoming Conferences

Tue, 31 May 2011 16:20:26 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live from the Jefferies 2011 Global Healthcare Conference on Monday, June 6, 2011, at 3:00 p.m. ET in New York City. In addition, Alkermes’ corporate presentation will be webcast live from the Goldman Sachs 32^nd Annual Global Healthcare Conference on Tuesday, June 7, 2011, at 5:10 p.m. ET (2:10 p.m. PT) in Rancho Palos Verdes, Calif. The presentations may be accessed under the investor relations tab at www.alkermes.com. The presentations will be archived for 14 days.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America California Massachusetts New York

INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical

MEDIA:

Logo

Alkermes’ Corporate Presentation to be Webcast at the UBS Global Specialty Pharmaceuticals Conference

Tue, 17 May 2011 16:20:38 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Specialty Pharmaceuticals Conference on Tuesday, May 24, 2011, at 11:00 a.m. BST (6:00 a.m. ET) from the UBS offices in London. The presentation may be accessed under the investor relations tab at www.alkermes.com and will be archived for 14 days.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Biotechnology Mental Health Pharmaceutical

MEDIA:

Logo

Alkermes to Host Conference Call to Discuss Fiscal Year 2011 Financial Results

Wed, 11 May 2011 16:20:42 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Wednesday, May 18, 2011, to discuss the company’s financial results for fiscal year ended March 31, 2011. Management will also provide financial expectations for fiscal year 2012.

A replay of the conference call will be available from 7:30 p.m. ET on Wednesday, May 18, 2011, through 5:00 p.m. ET on Wednesday, May 25, 2011, and may be accessed by visiting Alkermes’ website or by dialing 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The replay access code is 6037988.

About Alkermes

VIVITROL^® is a trademark of Alkermes, Inc. RISPERDAL^® CONSTA^® is a trademark of Janssen-Cilag group of companies.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical

MEDIA:

Logo

Alkermes’ Corporate Presentation to Be Webcast at the Cowen Health Care Conference

Mon, 28 Feb 2011 16:20:39 -0500

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Cowen 31^st Annual Health Care Conference on Monday, March 7, 2011, at 2:30 p.m. ET from the Boston Marriott Copley Place. The presentation may be accessed under the investor relations tab at www.alkermes.com and will be archived for 14 days.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical

MEDIA:

Logo

Alkermes’ Corporate Presentation to be Webcast at the BIO CEO & Investor Conference

Tue, 08 Feb 2011 16:20:34 -0500

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the BIO CEO & Investor Conference on Tuesday, February 15, 2011, at 9:30 a.m. ET from the Waldorf Astoria in New York City. The presentation may be accessed under the investor relations tab at www.alkermes.com and will be archived for 14 days.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America Massachusetts New York

INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Research Science

MEDIA:

Logo

Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2011

Thu, 27 Jan 2011 16:20:35 -0500

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Thursday, February 3, 2011, to discuss the company’s financial results for the third quarter of fiscal 2011. Management will review the quarter and provide an update on the company.

A replay of the conference call will be available from 7:30 p.m. ET on Thursday, February 3, 2011, through 5:00 p.m. ET on Thursday, February 10, 2011, and may be accessed by visiting Alkermes’ website or by dialing 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The replay access code is 6037988.

About Alkermes

VIVITROL^® is a trademark of Alkermes, Inc. RISPERDAL^® CONSTA^® is a trademark of Janssen-Cilag group of companies.

CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Research Science

MEDIA:

Logo